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Typology of the Primary Outcome Construction in
Dermatology: A Systematic Review of Published
Randomized Controlled Trials
Dany Nassar1, Emilie Sbidian2,3,4, Sylvie Bastuji-Garin2,3, Ludovic Martin5,6 and Alain Dupuy7,8,9
The primary outcome is a major component of a randomized clinical trial (RCT) and several types of outcome
can be chosen in a given disease. We systematically reviewed RCTs on nonneoplastic dermatological diseases
published in 2009 and referenced in Medline, and described how the main outcome was defined and
constructed. We assessed whether those characteristics were associated with a clearly defined primary outcome
and whether they were associated with a significant statistical test for the primary outcome. Outcome
construction variables were the three ‘‘VIP’’ questions (V denoting Variable: binary vs. quantitative variable; I
denoting Item: data collection based on multiple vs. single item(s); and P denoting time Points: outcome
assessment based on a ‘‘final time point’’ vs. ‘‘final and initial time points’’). Among 122 RCTs, 32% did not have a
clearly defined primary outcome. In multivariable analyses, a clearly defined primary outcome was associated
with a binary variable (odds ratio (OR)¼ 6.7; 2.5–17.7) and the composite variable ‘‘both blinding/placebo-
controlled arm’’ (OR¼ 4.5; 1.8–11.2); a significant statistical test was associated with a ‘‘final time point’’–based
outcome construction (OR¼ 2.6; 1.2–5.5). Our study points to areas of improvement related to the definition and
construction of the primary outcome in RCTs in dermatology.
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INTRODUCTION
Randomized controlled trials (RCTs) are the gold standard
method to assess the efficacy of an intervention in medicine.
RCT methodology has been extensively explored over the
past decades, and numerous textbooks are dedicated to the
design of RCTs. Reporting guidelines such as the CONSORT
statement have been endorsed by a majority of leading
medical journals including the Journal of Investigative
Dermatology (Begg et al., 1996; Moher et al., 2001; Schulz
et al., 2010; Williams, 2010). However, poor reporting has
long been demonstrated; improvement is still needed (Dwan
et al., 2008; Hopewell et al., 2010), and dermatology is no
exception (Bigby et al., 1985; Williams and Goldsmith, 2006;
Alvarez et al., 2009; Williams, 2010).
Recently, a great deal of methodological research has
focused on primary outcome–related issues. Outcome report-
ing bias has emerged as a major issue in clinical research
(Chan et al., 2004; Chan and Altman, 2005b; Mathieu et al.,
2009). Reporting of poorly defined outcomes has also been
shown to be pervasive (Chan and Altman, 2005a; Hopewell
et al., 2010). In addition, in dermatology, a multiplicity of
scales and scores are used for a given disease, but few of
them have been properly validated (Schmitt et al., 2007;
Spuls et al., 2010).
In this study, we focused on an original aspect of the
outcome-related issues by assessing the type of construction
across a large variety of diseases. We systematically reviewed
the characteristics of the primary outcome in published
dermatology randomized trials. Our initial hypothesis was
that, across a large variety of diseases, the type of construc-
tion of the primary outcome might be associated with the
quality of definition and might be biased toward statistically
significant results.
RESULTS
Characteristics of the selected articles
Our initial search identified 667 articles, and 122 of them met
our inclusion criteria (Figure 1 and complete list of articles in
Supplementary Data 1 online). Sixty-seven (55%) articles
had been published in a Dermatology specialty journal.
Forty (33%) trials included p30 subjects, and 49 trials
(40%) included 4100 subjects. Other trial and journal
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characteristics are presented in Table 1 and Supplementary
Data 2 online.
Primary outcome definition
We identified one clearly defined primary outcome in 83
(68%) articles. The 39 (32%) remaining articles had an
unclear definition of their primary outcome (Table 2).
Type of outcome construction
Regardless of the disease and the outcome, we were able to
‘‘deconstruct’’ the outcome by addressing the three ‘‘VIP’’
questions (Table 3; see Materials and Methods for details).
The variable used to classify the patient was binary in 55
(45%) articles. ‘‘Final and initial time point’’–based outcome
constructions were used in 66 (54%) articles. Multi-item–-
based outcome was used in 40 (33%) articles. Other
descriptive characteristics of the primary outcome (e.g.,
method of disease assessment, number of evaluators, and so
on) are presented in Supplementary Data 2 online.
Factors associated with a clear definition of the primary
outcome
A clear outcome definition was significantly associated with a
higher journal impact factor (IF), larger trials, industry funding,
blinding, a placebo-controlled arm, and a binary outcome
variable (Table 4). A significant effect modification between
the placebo-controlled arm and blinding was observed
(P¼ 0.02). Therefore, for multivariate purpose, we used a
composite variable: no blinding and no placebo-controlled
arm (reference category), either blinding or placebo-controlled
arm, and both blinding and placebo-controlled arm. In the
multivariable analysis, the binary outcome variable (odds ratio
(OR)¼ 6.7; 2.5–17.7) and the interaction term ‘‘both blinded
trial and placebo-controlled arm’’ (OR¼4.5; 1.8–11.2) were
the only remaining factors significantly associated with a clear
outcome definition. Industry funding strongly associated with
blinding (P¼0.007) and larger trials strongly associated with
binary outcome variable (Po104) were not independently
Search result
n =667
Articles published in
journals with IF <2:
n =316
Excluded articles, n =229
Not skin disease: n =34
Oncodermatology: n =30
Not dermatological outcome (e.g., pulmonary
hypertension in scleroderma): n =12
Selected articles
n =122
Not RCT, phase I, analysis of subgroup of RCT: n =127
Not therapeutic trial (safety, score validation),
pathophysiological studies (not clinical outcome):
n =26
Figure 1. Flowchart depicting the procedure of article selection. IF, impact
factor; RCT, randomized controlled trial.
Table 1. General characteristics of the 122 selected
trials
Publication characteristics n (%)
Dermatology journal specialty 67 (55)
Impact factor (IF; 2008)
2oIFo3 53 (43)
X3 69 (57)
Multisite study 51 (42)
Blindness (as mentioned)
Nonblinded or unclear 26 (21)
Blinded 96 (79)
Number of randomized patients
p30 40 (33)
30–100 33 (27)
4100 49 (40)
Type of treatment
Topical/intralesional 49 (40)
Systemic 31 (25)
UV/phototherapy/laser 25 (20)
Other 5 (4)
Combination 12 (10)
Aim of treatment
Curative 103 (84)
Preventive 19 (16)
Controlled group
Active treatment 52 (43)
Placebo or nonactive 70 (57)
Type of disease
Inflammatory dermatosis 56 (46)
Infectious dermatosis 23 (19)
Ulcers/keloids/lipoatrophy and regenerative disorders 19 (15)
Other 24 (20)
Trial duration
p3 Months 76 (62)
43 Months 46 (38)
Industry funding 58 (48)
Table 2. Primary outcome definition
Definition of the primary outcome n (%)
Clear definition of a primary outcome 83 (68)
Unclear definition of a primary outcome 39 (32)
Stated primary outcome but unclear definition 6 (5)
Several outcomes stated as primary 8 (7)
No outcome stated as primary 25 (20)
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associated with a clear outcome definition in the multivariate
analysis (P40.20).
Factors associated with a significant statistical test
Among the 122 included articles, 67 (55%) had a significant
statistical test result for the ‘‘primary outcome’’, 42 (34%)
had a nonsignificant statistical test, and 13 (11%) did not
present any information on the statistical significance. In
univariable analysis, four variables were associated, or
nearly associated, with a significant statistical test result:
industry funding, blinding, a ‘‘final-only time point’’–based
outcome construction, and a clearly defined primary out-
come (Table 5). No significant interaction was observed
between these parameters. In the multivariable analysis,
‘‘final-only time point’’–based outcome construction
(OR¼2.6; 1.2–5.5) was the only variable associated with
a significant statistical test result for the primary outcome; a
clearly defined primary outcome trended to be associated
(OR¼2.2; 1–4.8).
DISCUSSION
In this study, we systematically assessed the definition and
the construction of the primary outcome in RCTs on
nonneoplastic dermatological diseases published in journals
with an IF of 42. We evidenced 34% of articles with an
unclear or undefined primary outcome. Regardless of the
disease and the outcome, the primary outcome could be
‘‘deconstructed’’ using three simple categories. These cate-
gories were associated with clarity of outcome definition and
with a significant statistical test result.
As a byproduct from this study, we propose a checklist of
what trialists, authors, editors, referees, and readers should
require for an outcome to be completely described. This
checklist proposal, entitled ‘‘Kipling’s six serving-men and
the blind VIP,’’ is presented in Box 1; we are confident that
these requirements could apply, beyond dermatology, to
outcome description of any medical specialty.
Table 3. Outcome construction method, ‘‘the VIP1
questions’’
Outcome construction method: ‘‘the VIP1 questions’’ n (%)
Variable type
Binary 55 (45)
Ordered categories 10 (8)
Quantitative 57 (47)
Items collected for outcome construction
Multi-items 40 (33)
Single item or global evaluation 82 (67)
Time points used for outcome construction
‘‘Final and initial time points’’ 66 (54)
‘‘Final-only time point’’ 56 (46)
1In VIP, V denotes Variable type in statistical analysis, I denotes Items
collected for disease evaluation, and P denotes time Points of disease
evaluation.
Table 4. Factors associated with a clearly defined primary outcome
Definition of the primary outcome
Clear (n=83), n
(%)
Unclear
(n=39), n (%)
Crude OR
(95% CI) P-value1
Adjusted OR2
(95% CI) P-value1
Dermatology specialty journal 47 (57) 20 (51) 1.2 (0.6–2.7) 0.6
Impact factor 43 52 (63) 17 (44) 2.2 (1.0–4.7) 0.05
Number of randomized patients 430 64 (77) 18 (46) 3.9 (1.7–8.8) 0.001
Blinded trial 70 (84) 26 (67) 2.7 (1.1–6.6) 0.03
Placebo-controlled arm 53 (64) 17 (44) 2.3 (0.2–0.9) 0.04
Blinded trial/placebo-controlled arm
None 1 —
Either blinded or placebo 1.2 (0.3–4.5) 0.81
Both blinded and placebo 4.5 (1.8–11.2) 0.001
Industry funding 46 (55) 12 (31) 2.8 (1.2–6.3) 0.01
‘‘VIP’’ outcome construction categories3
Binary variable 48 (58) 7 (18) 6.3 (2.5–15.8) o104 6.7 (2.5–17.7) o104
Multi-item-based outcome 29 (35) 11 (28) 1.4 (0.6–3.1) 0.5
‘‘Final-only time point’’–based outcome 41 (49) 15 (38) 1.6 (0.7–3.4) 0.3
Abbreviations: CI, confidence interval; OR, odds ratio.
1The P-value by w2 test or Fisher’s exact test, as appropriate.
2In multivariable analysis, OR was adjusted on the variables selected in the column.
3VIP categories are: Variable=binary versus quantitative; Items (used for data collection)=multi-item versus single-item/global evaluation; time Points (used
for outcome construction)=‘‘final-only time point’’ versus ‘‘final and initial time points.’’ See Materials and Methods for more detail.
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Other studies have demonstrated high figures for deficient
definition of the primary outcome across several medical
specialties (Chan and Altman, 2005a; Hopewell et al., 2010).
The association demonstrated in our study between blinding,
a binary end-variable, and a clearly defined outcome
probably reflects elements associated in higher-quality trials.
The type of the end-variable, one of the ‘‘VIP’’ questions, is
an original input from this study. Addressing the three ‘‘VIP’’
questions when designing a trial helps in understanding the
difference between scoring on a severity scale and assessing
an outcome. A given score (e.g., psoriasis area and severity
index (PASI)) can be incorporated into distinct outcome
constructions. We believe that the three ‘‘VIP’’ questions
used in this study may help clarify this important distinction.
Examples of various combinations for these three outcome
construction elements are presented in Supplementary Data 3
online. Discussing in detail the relevance of the methodolo-
gical choices underlying outcome construction is beyond the
scope of this article. In addition, the relevance of these
general methodological options is probably best discussed
disease by disease. However, regardless of the disease, we
believe that attributing to the patient a binary value conveys a
general benefit, as a final binary value corresponds to the two
generic categories of ‘‘Improved’’ versus ‘‘Not-enough
improved’’ or ‘‘Success’’ versus ‘‘Failure’’ (translating in
‘‘Dead’’ vs. ‘‘Alive’’ or ‘‘Cured’’ vs. ‘‘Not cured’’ in life-
threatening and acute diseases). This final step for classifying
the patient in a binary way implies a decision on what
amount of improvement is a clinically meaningful improve-
ment. This call may result from a consensus among
clinicians, from regulatory agencies’ requirements, or may
be deducted from studies specifically designed to establish
clinically meaningful thresholds (Tubach et al., 2005, 2006,
2007). Although categorizing quantitative variables have
several statistical drawbacks (Del Priore et al., 1997; Altman
and Royston, 2006), a specific approach may be argued for
outcome-related variables because a binary expression is
directly related to the therapeutic decision. In addition, when
using a binary end-variable at the group level, the therapeutic
benefit translates into a percentage of ‘‘improved’’ or cured
patients, which can be viewed intuitively as a more clinically
meaningful information for the reader than an average score
flanked with a range of dispersion.
Our specific initial hypothesis was that using a quantita-
tive end-variable, rather than a binary one, would be
associated with a statistically significant result. This hypoth-
esis was not verified. The only independent variable
associated with a significant statistical test result was again
one of the three original construction variables introduced
in this study (‘‘Final-only time point’’–based construction
method). The interpretation of this association is not
straightforward. The first step should be to reproduce these
results in an independent sample of articles. The main
difficulty lies in the impossibility to disentangle, among trials
with a positive statistical test result, the part due to bias from
the part reflecting true differences between randomization
groups.
Some limitations of our study should be discussed. First,
one could argue that analysis on the primary outcome should
be done disease by disease. As we did not intend to discuss
the clinical relevance of the choices, and rather focused on
the methodological aspects, it was important to get a sample
of varied situations. With our approach, however, disease-
related factors could not be analyzed. Second, including
journals with an IF of o2 would have changed our figures
and conclusions. The justification of introducing an IF
Table 5. Factors associated with a statistically significant result for the primary outcome
Result of the statistical test
Significant (n=67),
n (%)
Nonsignificant or not
reported (n=55), n (%)
Crude OR
(95% CI) P-value1
Adjusted OR2
(95% CI) P-value1
Dermatology specialty journal 35 (52) 32 (58) 0.8 (0.4–1.6) 0.5
Impact factor 43 38 (57) 31 (56) 1.0 (0.5–2.1) 0.9
Number of randomized patients 430 46 (68) 36 (65) 1.2 (0.6–2.5) 0.7
Blinded 56 (83) 40 (73) 1.9 (0.8–4.6) 0.15
Placebo-controlled arm 41 (61) 29 (53) 1.4 (0.7–2.9) 0.3
Industry funding 36 (54) 22 (40) 1.7 (0.8–3.6) 0.13
‘‘VIP’’ outcome construction categories3
Binary variable 32 (48) 23 (42) 1.3 (0.6–2.6) 0.5
Multi-item-based outcome 25 (37) 15 (27) 1.7 (0.7–3.3) 0.3
‘‘Final-only time point’’–based outcome 38 (57) 18 (33) 2.7 (1.3–5.7) 0.09 2.6 (1.2–5.5) 0.01
Clear definition of the primary outcome 51 (76) 32 (58) 2.3 (1.1–5.0) 0.04 2.2 (1–4.8) 0.06
Abbreviations: CI, confidence interval; OR, odds ratio.
1The P-value by w2 test or Fisher’s exact test, as appropriate.
2In multivariable analysis, OR was adjusted on the variables selected in the column.
3VIP categories are: Variable=binary versus quantitative; Items (data collection)=multi-item versus single-item/global evaluation; time Points (used for
outcome construction)=‘‘Final-only time point’’ versus ‘‘Final and initial time points.’’ See Materials and Methods for more detail.
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threshold was to limit our analysis to journals with
presumably more stringent reviewing criteria for RCT
methodology and reporting.
In summary, our study points to areas of improvement
related to the primary outcome in RCTs in dermatology, and
we emphasize the importance of outcome construction in the
critical appraisal of the whole judgment process.
MATERIALS AND METHODS
Search strategy
We performed a cross-sectional study of RCTs in dermatology
published in 2009. Trial search was made on the National Library
of Medicine Medline database using the PubMed interface. We
identified the RCTs using the Cochrane Collaboration–recommended
search strategy (Higgins et al., 2009). We limited our search to studies
in humans, published in English language, and between 01 January
2009 and 31 December 2009. We further excluded articles without
abstracts, and those indexed as reviews or meta-analyses. The search
was last updated on 24 August 2010. This search yielded 667 articles.
Article selection
We further selected articles published in journals with an IF of 42
according to Journal Citation Reports (Thomson Reuters 2008), and
obtained 351 citations. On the basis of title and abstract reading, and
the whole text if deemed necessary, one of us (DN) selected the RCTs
conducted on nonneoplastic skin diseases, using a clinical outcome
as the main outcome. Oncology was excluded because of the
supposed low variability in outcome construction across diseases, as
consensual evaluation guidelines, such as RECIST criteria or similar
ones, are predominant in the field (Eisenhauer et al., 2009).
As this study was exploratory, introducing the outcome con-
struction variables, we did not define an appropriate sample size,
and rather used a convenience sample of all consecutive suitable
articles published in 2009.
Data abstraction
Each article was randomly attributed to two authors among four
(DN, ES, SB-G, and AD). Data abstraction was made using a MS
Excel abstract form. Discrepancies were automatically detected and
resolved by discussion between the two assessors; disagreements
were resolved by discussion among the four assessors.
Assessment of the primary outcome
Selection and definition of the ‘‘primary outcome’’. We
proceeded in two steps: (1) If there was an outcome clearly stated in
the article as being the primary outcome, we classified the article as
having a ‘‘clearly defined primary outcome’’. Otherwise, the article
was classified as having an ‘‘unclearly defined primary outcome’’.
(2) Further, we needed to assess the construction of an outcome for
each article (cf, subsequent section ‘‘Outcome construction’’). The
outcome analyzed was the primary outcome in articles classified as
having a clearly defined primary outcome. In the articles without a
clearly defined primary outcome, we selected the outcome used for
sample size calculation if there was any (n¼ 6), or, alternatively, the
first outcome to appear in the results (n¼ 25).
Exceptions were as follows: if the stated primary outcome was
unclearly defined, we actually classified the article as having an
‘‘unclearly defined primary outcome’’ (n¼ 6). Another exception
was the situation of multiple primary outcomes. We classified the
article as having a ‘‘clearly defined primary outcome’’ if the article
presented true coprimary outcomes; alternatively, we classified the
article as having an ‘‘unclearly defined primary outcome’’ if the
article was confusing in that it presented multiple so-called primary
outcomes.
Outcome construction. We categorized the construction of the
outcome by addressing three important questions, namely ‘‘VIP’’
questions, standing, respectively, for ‘‘Variable,’’ ‘‘Items,’’ and ‘‘time
Points.’’ The ‘‘Variable’’ category classified the outcome according
to whether the final variable attributed to the patient was categorical
(almost always binary) or quantitative. The ‘‘Items’’ category referred
to the initial step of collecting the data. Either multiple elementary
items were scored and then mathematically combined into a single
variable (referred to as ‘‘Multi-items’’) or a global evaluation was
made directly—or one single item was scored—with no need for a
Box 1. Checklist proposal for the (primary) outcome
description
‘‘Kipling’s six honest serving-men and the blind VIP.’’
1. Kipling’s six honest serving-men1: why, what, when, where, who,
and how?
Why was this outcome chosen as the primary outcome?
What was the supporting ‘‘material’’ (e.g., photographs, lab result,
patienty)?
When was the final evaluation made (including serial evaluation in
censored data analysis)?
Who made the evaluation (e.g., the treating physician, one or more
independent evaluator(s), the patient, an automatic devicey)? If
several evaluators were required, was a harmonization process
implemented? How were conflicted evaluations on the same material
handled?
Where was the evaluation made (usually the setting of the trial)?
How was the evaluation made, i.e., any process used for collecting
the elementary items used for the outcome construction? If several
items had to be combined, how was that done, i.e., using what
algebraic or logical rule?
2. ‘‘Blind’’
Any procedure for implementing blinding should be described. Any
procedure to evaluate the quality of blinding should be presented.
Nonblinding during evaluation of the outcome conveys a risk of
biased assessment.
3. The three ‘‘VIP’’ questions for outcome construction
The three ‘‘VIP’’ questions (‘‘Variable,’’ ‘‘Items,’’ and ‘‘time Points’’)
may appear as technical ones, but any clear description of an
outcome allows rapid and unambiguous answers to these questions.
a. What type of variable was attributed to a patient (binary,
quantitative, other)?
b. What type of information was collected? Multiple items? Single
item? Or a global evaluation?
c. What time points were used to construct the outcome : initial and
final time points, or only final time point (‘‘direct assessment of
change’’ is a special case of ‘‘initial and final’’)?
1Refers to Rudyard Kipling’s poem ‘‘I keep six honest serving-men,’’ The
Elephant’s Child, Just So Stories (1902).
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combination rule (referred to as ‘‘global or single item’’). The ‘‘time
Points’’ category referred to whether the outcome used only the final
state (referred to as a ‘‘final time point’’–based construction) or a
combination of initial and final states (referred to as ‘‘initial and final
time point’’–based outcome construction). We classified survival
analysis as a subcategory of the ‘‘Final time point’’ group and direct
assessment of change using both initial and final photographs, as a
subcategory of the ‘‘Initial and Final time point’’ category. Various
examples of combining the three ‘‘VIP’’ categories are presented in
Supplementary Data 3 online.
Other characteristics of the judgment process were also recorded:
Who made the evaluation (the patient, one or several care
provider(s), one or several independent investigator(s), or using a
tool-based measurement)? and on what ‘‘material’’ (the patient,
photographs, or other types of documents)?
Other variables assessed
We collected various journal characteristics (2008 IF, dermatology
specialty journal or not, and so on) and trial descriptive character-
istics. We also assessed whether the result of the statistical test for the
primary outcome was ‘‘significant,’’ ‘‘nonsignificant,’’ or unstated,
using the significance level stated by the authors (usually 0.05).
Data analysis
Qualitative variables were described as number (%). All tests were
two tailed and P-values of o0.05 were considered statistically
significant. Two quantitative variables were dichotomized: below or
above 3 for the IF (the rounded value of the median) and below or
above 30 for the number of randomized patients (to separate small
and large trials).
A first analysis was conducted to identify the variables associated
with a clearly defined primary outcome, and a second one to identify
which variables were associated with a statistically significant result
for the primary outcome. Logistic models were fitted to estimate ORs
with their 95% confidence intervals. Variables yielding p-values of
o0.20 in the univariate analyses were considered for multivariate
analysis. Potential interactions were assessed by pairwise analyses
and confounding by fitting multiplicative models. In case of
significant interaction, an additional variable composed of the
product of the two variables was built (Schumacker and Marcou-
lides, 1998). Final backward step-by-step logistic regression analyses
were conducted. The analysis was conducted using the SAS software
v9.2 (SAS, Cary, NC).
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